Morgan Stanley Purchases 302,027 Shares of Davita Inc (DVA)
Morgan Stanley lifted its position in Davita Inc (NYSE:DVA) by 46.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 946,208 shares of the company’s stock after acquiring an additional 302,027 shares during the quarter. Morgan Stanley owned 0.57% of Davita worth $65,704,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new stake in shares of Davita in the second quarter valued at about $3,421,000. OppenheimerFunds Inc. raised its holdings in shares of Davita by 58.7% in the second quarter. OppenheimerFunds Inc. now owns 4,066,317 shares of the company’s stock valued at $282,365,000 after acquiring an additional 1,504,347 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in Davita in the second quarter worth about $1,627,000. Alps Advisors Inc. raised its holdings in Davita by 11.1% in the second quarter. Alps Advisors Inc. now owns 10,781 shares of the company’s stock worth $749,000 after purchasing an additional 1,080 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Davita by 3.0% in the second quarter. Janus Henderson Group PLC now owns 1,284,092 shares of the company’s stock worth $89,168,000 after purchasing an additional 37,362 shares in the last quarter. Hedge funds and other institutional investors own 87.71% of the company’s stock.
DVA has been the subject of a number of recent research reports. William Blair reiterated a “buy” rating on shares of Davita in a report on Wednesday, June 6th. Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $78.00 target price for the company in a report on Monday, July 9th. Finally, JPMorgan Chase & Co. upgraded shares of Davita from an “underweight” rating to a “neutral” rating in a report on Thursday, September 13th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Davita currently has an average rating of “Buy” and an average target price of $82.13.
Davita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, August 1st. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Davita had a return on equity of 14.49% and a net margin of 4.30%. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.88 billion. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. sell-side analysts predict that Davita Inc will post 4 EPS for the current year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: Find a Trading Strategy That Works
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.